Report Overview

The HPV Vaccine market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The increasing prevalence of cervical cancer among women of reproductive age is a key factor boosting the Human Papillomavirus Vaccine market growth in Kenya. Human Papilloma Virus (HPV) is responsible for 70% of all the cervical cancer cases. According to WHO, the East African region has the highest burden of cervical cancer in the world. In Kenya, approximately 5,250 new cases are diagnosed annually. Immunization of girls before the exposure to the virus can prevent up to 90% of all cervical cancer cases.



Market Drivers

HPV vaccine market is majorly driven by the high prevalence of cervical cancer in Kenya. Cervical Cancer is amongst the leading causes of cancer deaths among women in Kenya. In 2018 alone, 49,000 new cancer cases were diagnosed, and 33,000 deaths documented. Nine women die from cervical Cancer in Kenya alone, every day.

The Government of Kenya is working with partners like GAVI, UNICEF and WHO to introduce HPV vaccine into their routine immunisation programme. World Health Organisation has recommended HPV vaccination to girls at ages 913 and Kenya has developed a comprehensive strategy to address cervical cancer, which includes rollout of HPV vaccination among girls.

Despite little prior knowledge of cervical cancer and HPV, and school-based vaccination, communities were interested in receiving HPV vaccination in Kenya.

One of the most crucial drivers of the market is the high efficacy and the protection provided by the vaccines against cervical cancer. All three vaccines have proved their efficacy and safety through clinical trials in protecting against HPV infections and cancer.

However, HPV vaccination presents unique challenges for implementation, given its three-dose series, protection against an infection that causes disease decades later, and target population of adolescent girls only.

HPV vaccines in populations whose immunological system may be challenged by multiple co-infections such as malaria and helminth infections are restricting factors for the growth of HPV vaccines market in Kenya.